Background: Bariatric surgery is the most effective long-term treatment for morbid obesity, reducing obesity-associated comorbidities. The purpose of the present study was to evaluate the UCP3 promotor (-55C-->T) polymorphism outcomes 1 year after biliopancreatic diversion in morbidly obese patients.
Methods: A sample of 40 morbidly obese patients (BMI >40 kg/m(2)) were operated. Weight, fat mass, blood pressure, basal glucose, triacylglycerols, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were measured at basal visit and at each visit. The frequency of patients with diabetes mellitus, hypertension, and hyperlipidemia was recorded at each visit.
Results: Twenty-eight patients (70%) had the genotype C/C (wild group) and 12 (30%) patients C/T (mutant group). In wild type group, body mass index, weight, fat mass, systolic blood pressure, glucose, total cholesterol, low-density lipoprotein cholesterol, and triacylglycerols concentrations decreased. In mutant type group, the same parameters improved, without statistical differences with wild group. Initial weight percent loss at 1 year of follow-up was similar in both genotypes (34.1% vs 28.6%; ns).
Conclusion: Polymorphism -55C/T of the UCP3 promotor did not have an effect on weight loss or clinical outcomes after bariatric surgery.